國盛金控(002670.SZ):2020年度由盈轉虧 預虧2.5億元–4.5億元
格隆匯 1 月 29日丨國盛金控(002670.SZ)披露2020年度業績預吿,預計2020年度歸屬於上市公司股東的淨虧損2.5億元–4.5億元,上年同期盈利9520.61萬元;扣除非經常性損益後的淨虧損2.53億元–4.55億元,上年同期虧損1.14億元。
報吿期內,公司以穩定經營、防範風險為首要任務,在經營方針、業務結構、業務規模等方面均進行了相應調整。公司營業收入增長、歸屬於上市公司股東的淨利潤下降的主要原因:1.證券經紀業務、投研業務收入大幅增長,相應成本費用較上年同期有所增加;2.證券自營業務收益較上年同期大幅下降;3.本期擬計提減值準備較上年同期有所增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.